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Establishment of galenic 
laboratories in developing 
countries to produce high 
quality medicines: results 
of Aid Progress Pharmacist 
Agreement (A.P.P.A.®) Project
AID PROGRESS PHARMACIST AGREEMENT PROJECT: 
AIMS IN DEVELOPING COUNTRIES
Aid Progress Pharmacist Agreement (A.P.P.A.®) is a non-prof-
it association based on voluntary work (1) and its main ac-
tivity is the A.P.P.A.® Project. The Project started in 2005 as a 
result of the cooperation between the Pharmacy Faculty 
of Turin and Italian community pharmacists. Its main task is 
the establishment of galenic laboratories (GLs) in hospitals 
of developing countries (DCs) according to the principles 
of international health cooperation.
Aims of the Project:
• establishing GLs in DCs with the aim of preparing medici-
nal products that comply with quality requirements, first 
of all to fight the widespread counterfeiting of medicines 
in DCs;
• tailoring the dosages and pharmaceutical forms accord-
ing to the actual patient needs;
• employing local staff, teaching them a “new job,” and 
opening a suitable school;
• minimizing the costs necessary to prepare these medi-
cines.
There are important reasons why galenics should be used:
i) low cost of the production system and the simple opera-
tive procedures;
ii) the possibility to adapt dosages and pharmaceutical 
forms to the patients’ needs and medical prescriptions;
iii) reduction in the use of counterfeit medicines in the 
settings where the GL is located.
The Project complies both with EU and participating coun-
tries’ legislation, while safeguarding the standard of medici-
nal products. It is the only project related to galenics research 
and development in the field of international health coop-
eration and the only one that involves close cooperation be-
tween the community pharmacies and the University. Many 
pharmacists have spent a lot of time doing humanitarian 
work in DCs but their efforts have not been long lasting. The 
collaboration with the University ensures the continuity of 
the Project and the constant quality control of the medicinal 
products. This guarantees that people living in DCs will use 
quality, safe, and efficacious medicines, rather than poten-
tially counterfeit industrial medicinal products.
The problem of counterfeit medicines is especially serious 
in DCs, where custom procedures are less stringent, com-
petent authorities’ controls are less effective, and the use 
of ineffective medicines may result in a substantial loss of 
public confidence in the health care system (2-10). The 
World Health Organization (WHO) defines counterfeit 
drugs as medicines that are deliberately and fraudulently 
mislabeled with respect to identity and/or source. Coun-
terfeit medicines include products with the correct ingre-
dients, but also with wrong ingredients, without active 
ingredients, with insufficient or excessive amount of ac-
tive ingredient, or with false or misleading labeling (11).
A part of the A.P.P.A.® Project is to investigate the quality of 
medicines purchased on site from pharmacies or unoffi-
cial street-pharmacists. This kind of investigation also helps 
to identify whether a setting is a potential candidate for 
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A.P.P.A.® Project: if drugs found on a particular market are of 
sufficient quality, there is no need for GL establishment.
A previous survey (12) collected samples in different DCs 
and analyzed them in the University of Turin laboratories. 
Most of the samples were manufactured in India. In fact, 
DCs usually import medicines as they have no production 
facilities and do not check their quality before distribu-
tion (13). We estimated that 50% of the tested items were 
substandard drugs and 2% were counterfeits without de-
clared active pharmaceutical ingredients (APIs) (12).
THE OPERATING STEPS OF THE A.P.P.A.® PROJECT
The location for establishment of a new A.P.P.A.® laboratory 
is selected on the basis of a specific request received from 
a DC health care facility. The usefulness of establishing a 
GL in a particular setting is assessed in a preliminary study. 
The study implies a trip of an A.P.P.A.® staff member to the 
site to assess the local situation and recipient areas (step 0 
of A.P.P.A.® Project). A precise protocol is used to obtain the 
preliminary information at this stage. Some medicines are 
purchased on site and sent to the laboratories of the Uni-
versity of Turin, where qualitative and quantitative analy-
sis is performed to assess their compliance with the stated 
characteristics. The feasibility study for a new A.P.P.A.® Proj-
ect consists of several stages and is specifically aimed at:
• finding a location for the galenic laboratory;
• identifying a partner for economic cooperation;
• acquainting the research group with the climatic condi-
tions (temperature and humidity) of the area of interest;
• establishing contacts with the local medical doctors 
(MDs) and the head of the host health facility;
• analyzing the most frequent endemic diseases in col-
laboration with the MDs in charge;
• gathering information on the catchment area of the 
health facility;
• identifying local actors, preferably already part of the 
health sector, to be taught by A.P.P.A.® students during 
their internships on site;
• ensuring a facility (minimum 30 m2) equipped with run-
ning water and electricity (with the possibility of install-
ing an air conditioner);
• assessing the possibility of buying substances (active in-
gredients and excipients) and equipment, or the possibil-
ity of importing them by analyzing customs restrictions 
and identifying the person responsible for the operation;
• analyzing local medicines to assess their quality stan-
dards and prices.
This information enables us:
• to conduct a pharmacoeconomic survey;
• to evaluate the feasibility of the Project;
• to prepare a specific handbook suited to the local 
needs;
• to prepare teaching materials for operators training.
After the feasibility study the A.P.P.A.® Project can start. 
The following six steps enable us to establish an effective 
and functional laboratory:
1. choosing the GL location. The Chief MD in charge of 
the medical center lists the local diseases and the correct 
pharmaceutical forms are planned;
2. at the galenic A.P.P.A.® laboratory at the University of 
Turin, Pharmacy students are taught how to make the re-
quired medicinal products during the preparation of their 
experimental thesis;
3. a local staff member visits the laboratory in Turin to 
learn the product preparation (about one month’s work) 
under the supervision of Italian Pharmacy students. Dur-
ing this period the material for the GL is sent to the DC 
hospital;
4. the local staff member who visited Turin undergoes a 
two-month training period at the DC hospital, coordinat-
ed by Italian Pharmacy students;
5. quality control of medicinal products prepared in the 
new GL; some of the samples are sent to the University of 
Turin to be quality tested;
6. regular 40-day or longer internships for Pharmacy stu-
dents from Italy organized each year to supervise the 
work of the laboratory and to study new formulations 
made according to the Chief MD’s demands.
ESTABLISHED LABORATORIES
After 8 years of work and due to the effort of about 90 peo-
ple, including graduates, undergraduates, and laboratory 
technicians 8 operating laboratories were established, all 
at the step 6 (1):
• Centre Médico-Chirurgical Maternité “la Bethanie”, Doua-
la, Cameroon, established in 2006.
• Hôpital “Notre Dame des Apòtres,” Garoua, Cameroon, es-
tablished in 2007
• Polyclinique Universitaire “Le Bon Samaritain,” A.T.C.P., 
N’Djamena ssud, Chad, established in 2008
• Centre Medico Social, Eglise Catholique Apostolique Ro-
maine, Ihosy, Madagascar, established in 2008
• Hôpital “Henintsoa,” Vohipeno, Madagascar, established 
in 2008
• Hospital “Nossa Senhora da Paz,” Compańia de Santa 
Teresa de Jesus, Cubal, Angola, established in 2011
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• A.M.E.N. Centro Mòdico, Funda, Angola, established in 2012
• Hospital “Saint Damien,” Tabarre, Republic of Haiti, estab-
lished in 2012
GALENIC MEDICINAL PRODUCTS AND ADMINISTERED 
THERAPIES
The laboratories produce liquid preparations, capsules, 
ointments, pessaries, and suppositories. The Project also 
plans to introduce multi-dose parenteral solutions. Medici-
nal products are made according to specific local needs 
and based on the WHO list of essential medicines for DCs 
(14). There is also a specific handbook prepared for each 
laboratory. More than 100 different formulations can be 
prepared, as well as pediatric dosages for each product. 
Pediatric formulations are very important since their avail-
ability is limited. The main pharmaceutical forms are sup-
pository and liquid preparations since can be easily modi-
fied to adapt to the weight of the child.
Angola and Haiti laboratories required more pediatric for-
mulations because of the large number of young patients. 
The Saint Damien Hospital on Haiti is the only pediatric 
hospital on the island and it treats about 80 000 children 
every year. Considering the high incidence of heart disease 
on site, a specific handbook was prepared for the Haiti GL, 
which included a number of preparations for the cardio-
vascular system.
Preparations for pediatric use produced so far are the fol-
lowing:
• Solutions: captopril, furosemide
• Suspensions: amoxicillin, carbocysteine, chlorampheni-
col, erythromycin, magnesium and aluminum hydroxide, 
metronidazole, vitamin B complex
• Syrups: ascorbic acid, carbocysteine, ibuprofen, iron sul-
fate, paracetamol, potassium canrenoate, propranolol, qui-
nine, ranitidine, salbutamol, vitamin B6
• Drops: nifedipine, quinine, ranitidine, salbutamol, vitamin 
B6
• Suppositories: paracetamol
The costs of raw materials and equipment since the open-
ing of the first laboratory in 2006 until December 2013 
amounted to about 190 000 €. We calculated the exact 
number of treatments administered considering the me-
dicinal product posology and the exact duration of each 
treatment (Table 1). For example, in the GL in Chad, with 
83 kg of acetylsalicylic acid, the average number of thera-
pies administered each year was 568 lower doses and 
15 563 higher doses (the lower dose is mg/cps and 
the higher dose -500 mg/cps- is three times more pre-
scribed). In all our laboratories 10 000 000 oral doses were 
administered.
ACTIONS TO ENSURE qUALITy
In order to ensure the quality of the products, which is a 
prerequisite for their safety and efficacy, galenics were pre-
pared, labeled, and stored according to standard proce-
dures and established methods. The specific operative pro-
cedures and handbook for each laboratory mirror specific 
local needs and guarantee the products’ quality (15,16). 
Operative procedures and handbooks are written in Eng-
lish, French, Portuguese, or other languages to ensure a 
better understanding and reproducibility of preparations.
The use of written operative procedures and quality con-
trols are required by the European law for the preparation 
of medicines. The DCs do not generally have a specific leg-
islation related to galenics and if they do, it is extremely de-
ficient and cannot ensure the quality of the products. How-
ever, in each new A.P.P.A.® laboratory, the head of the health 
care facility has a duty to inform the local competent author-
ity. Sometimes, the local authorities have specific structural 
requests. For example, the Government of Madagascar re-
quired that each room in the laboratory is dedicated to pro-
ducing a different type of preparation, eg, solid or liquid.
The control and quality assurance is performed on site and 
in Italy (the tests applied are listed in Table 2). Each assay is 
carried out using instruments and methods in compliance 
with the Official Pharmacopoeia of the European Union (Ph. 
Eur. 7 ed. (Table 3) (17), although the European standard im-
poses simpler controls for galenics than those listed and the 
tests are normally required only for industrial medicines.
The results of quality controls are not always positive, as 
shown on the example from the N’Djamena laboratory 
(Figure 1). Negative results can be caused by technical and 
environmental factors. One of the technical factors is insuf-
ficient mixing time for powders, which does not allow uni-
form distribution of the active substance in the capsules. 
Environmental problems are usually related to atmospher-
ic humidity. Humidity is normally controlled by air condi-
tioners but in DCs the electricity is not always continuously 
available. Whenever the results of quality controls are not 
satisfactory, preparatory work stops until the arrival of a 
member of A.P.P.A.® association. After the cause is identified 
and removed, the checks are repeated and if the outcome 
is positive, the activity is resumed.
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STABILITy ASSESSMENT OF GALENICS
A.P.P.A.® performed a survey on the stability of various ga-
lenic dosage forms under different environmental condi-
tions in accordance with the EMA guidelines (12).
We gathered information on the stability of galenics in 
extreme environmental conditions (high temperatures 
and relative humidity) resembling those in target coun-
tries – “accelerated” (t = 40 ± 2°C, RH = 60 ± 5%) and “stress” 
(t = 40 ± 2°C; RH = 80 ± 5%) conditions. The main goal was 
to allow the preservation of preparations in facilities not 
equipped with air conditioners or refrigerators.
SELECTION AND TRAINING OF LOCAL STAFF
The local staff is selected by the head of the health facil-
ity. Preferably, they should have working experience in the 
health field but experience with galenics preparation is not 
necessary because they undergo training by the A.P.P.A.® 
staff. In addition, in the target countries it is almost impos-
sible to find staff with this kind of background knowledge. 
The training program is constantly assessed through week-
ly quizzes and quality control of the prepared medicines. 
When the local staff proves to be able to apply all the proce-
dures, galenic medicines are administered to the patients.
THE ROLE OF PHARMACy STUDENTS
A distinctive feature of this Project is the involvement of stu-
dents from the University of Turin, who use the Project as the 
basis for their thesis preparation. The students undergo an 
intensive training on technological procedures and the prin-
ciples of the international health cooperation and their work 
is constantly monitored by the University of Turin.
USE OF GALENICS IN DCS: ECONOMIC AND SOCIAL 
EVALUATIONS
The costs of equipment and raw materials are covered by 
funds raised through the collaboration of groups involved 
in international cooperation in health. The hospital can 
also use the funds earned by dispensing the medicinal 
products to buy raw materials. As a result there will be an 
uninterrupted production and the laboratory will be self-
financed. The sale of galenic products is managed entirely 
by the health care facility where the laboratory is located.
Galenic sale price on local market is usually equal to the 
production cost. Raw materials are purchased from the 
same suppliers for all eight laboratories because they have 
provided the lowest price without a decrease in raw mate-
rials quality. This is why the production cost is always the 
same regardless of the country.
Galenics are sometimes more expensive than the corre-
sponding industrial medicines available on the local mar-
TABLE 1. The number of capsules prepared in the A.P.P.A.® labo-
ratories in the world from 2006 to 2013
Active principle
The number 
of capsules 
produced
Acetylsalicylic acid 496,000
Acyclovir 500
Allopurinol 10,000
Aluminum hydroxide + magnesium hydroxide 172,500
Aminophylline 70,000
Amoxicillin 1,374,273
Atenolol 46,667
Bisacodyl 34,000
Captopril 76,000
Carbocysteine 23,600
Chloramphenicol 83,920
Ciprofloxacin 82,667
Diclofenac 428,000
Erythromycin 75,733
Ethambutol + isoniazid 80,000
Folic acid 331,400
Furosemide 261,538
Hydrochlorothiazide 99,000
Ibuprofen 724,167
Iron sulfate + folic acid 478,750
Loperamide 50,000
Mebendazole 185,143
Metformin 94,074
Metoclopramide 20,000
Metronidazole 583,867
Nifedipine 270,000
Nimesulide 36,500
Paracetamol 1,521,176
Praziquantel 4,167
Prednisolone 226,000
Quinine sulfate 242,983
Ranitidine 115,091
Rifampicin + isoniazid 44,667
Salbutamol 1,080,000
Verapamil 1,250
Vitamin B complex (B1 + B2 + B3 + B5 + B6) 288,889
Vitamin B12 133,333
Vitamin C 211,543
TOTAL 10,057,397
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ket as those prices are adapted to the purchasing power 
of the local population. The same Galenic product may 
be cheaper than the industrial product in one country 
but not in another. For example, considering the 2013 
list price, the cost of an amoxicillin 500 mg capsule pro-
duced in an A.P.P.A.® laboratory was € 0.04373. The cost of 
an equivalent industrial product in Chad was € 0.04231 
and in Angola € 0.05020. Considering only the production 
TABLE 2. Tests performed for quality assurance and control of galenic medicinal products (16,17)
Tests performed in the laboratories located in DCs Tests performed in the University of Turin laboratories
Raw materials
• Organoleptic control
• Melting point (Ph. Eur. Monograph 2.2.14) (17)
• Organoleptic control
• Melting point (Ph. Eur. Monograph 2.2.14)
• Spectrophotometric analysis
Pharmaceuticals forms
Infusions, liquid preparations for cutaneous application, liquid preparations for oral use, pessaries, hard capsules, semi-solid preparations 
for cutaneous application, suppositories
• Verification of the procedures accuracy
• Control of aspect
• Control of the product amount aimed for the market
• Control of the solidity of packaging
• Uniformity of content (Ph. Eur. Assay 2.9.6)
Infusions
• Sterility test (Ph. Eur. Assay 2.6.1)
• Bacterial endotoxins (Ph. Eur. Assay 2.6.14)
Liquid preparations for cutaneous application
• pH (Ph. Eur. Monograph 2.2.3) • pH (Ph. Eur. Monograph 2.2.3)
Liquid preparations for oral use
• pH (Ph. Eur. Monograph 2.2.3) • pH (Ph. Eur. Monograph 2.2.3)
Pessaries
• Uniformity of mass (Ph. Eur. Assay 2.9.5) • Uniformity of mass (Ph. Eur. Assay 2.9.5)
• Disintegration (Ph. Eur. Assay 2.9.2)
Hard capsules
• Uniformity of mass (Ph. Eur. Assay 2.9.5) • Uniformity of mass (Ph. Eur. Assay 2.9.5)
• Disintegration (Ph. Eur. Assay 2.9.1)
Suppositories
• Uniformity of mass (Ph. Eur. Assay 2.9.5) • Uniformity of mass (Ph. Eur. Assay 2.9.5)
• Disintegration (Ph. Eur. Assay 2.9.2)
TABLE 3. Acceptance criteria for quality assurance and control tests of galenic medicinal products (16,17)
Analysis Method of reference reported in Ph. Eur. Acceptance criteria
pH Monograph 2.2.3 The pH does not differ from the expected value
Melting point Monograph 2.2.14 The melting point does not differ from the value in the monograph
Uniformity of content Assay 2.9.6 The content is between 85% and 115% of the average content
Uniformity of mass Assay 2.9.5 Not more than two of the individual masses deviate from the aver-
age mass by more than ±10% and none deviates by more than ±20% 
(20 dosage units)
Disintegration Assay 2.9.1
Assay 2.9.2
At the end of the specified period all of the dosage units must have 
disintegrated completely
Sterility test Assay 2.6.1 At intervals during the incubation period and at its conclusion, 
examine the media for macroscopic evidence of microbial growth: 
If no evidence of microbial growth is found, the product complies 
with the test for sterility
Bacterial endotoxins Assay 2.6.14 The test is considered valid when all replicates of tested solutions 
show no reaction and the result of control solution confirms the 
labeled lysate sensitivity
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price, the amoxicillin 500 mg capsules were cost-effective 
in Angola but not in Chad. Generally, the galenic medi-
cines were 100% cost-effective in Angola, 62% in Chad, 
73% in Cameroon, and 75% on Madagascar. On Haiti, this 
evaluation was not applicable because pediatric prepara-
tions equivalent to those prepared in the laboratory were 
not available on-site.
A higher price of the galenic medicinal product compared 
to the corresponding industrial product could discourage 
patients to purchase it. In this respect, the health care facil-
ity will have the task to sensitize the purchasers about the 
importance of the quality of medicinal products. In addi-
tion A.P.P.A.® is responsible to continuously search for qual-
ity suppliers that can decrease the costs. It is difficult to 
achieve the economic autonomy of a GL because in order 
to obtain a significant gain from the sale of galenics, the 
hospital should increase the selling prices.
Therefore, different scenarios regarding the economic in-
dependence of the GLs can be considered. For example in 
Cameroon the incomes gained by the sale of galenics are 
enough to sustain the administration of the “la Bethanie” 
medical center in Douala. On the contrary, GL in the “Hen-
intsoa” Hospital in Vohipeno on Madagascar still needs do-
nor contributions. Our commitment is also to raise funds 
through the collaboration of groups involved in the inter-
national health cooperation to ensure the continued ac-
tivities regardless of the economic autonomy.
The current results are satisfactory, but achieving them re-
quired overcoming many difficulties. The main difficulties 
were not scientific but related to bureaucratic and techni-
cal problems, such as the electricity or running water sup-
ply. Another problem was migration of the local staff, who 
moved to the richer areas attracted by better economic 
prospects, which required re-recruiting and training new 
personnel.
CONCLUSIONS
The Project achieved many goals, the most important of 
which was to enable local people the access to quality me-
dicinal products in spite of the widespread distribution of 
counterfeit medicines in DCs. Great satisfaction has also 
come from the fact that hospital patients and their MDs 
believed that galenics were more effective than products 
from street vendors or pharmacies.
According to the principles of international cooperation, 
the final goal of our Project is that all laboratories become 
autonomous. Taking into account the results of quality 
controls and the stable employment of local staff, a labora-
tory can become technologically independent after about 
5 years’ work. Technological independence means that lo-
cal operators are able to effectively comply with all opera-
tive procedures, self-organize the production, and ensure 
a constant availability of products to meet the hospital’s 
needs.
The effective compliance with the operating procedures 
was verified through the quality controls by the University 
of Turin and it can be concluded that respecting the oper-
ating procedures largely contributes to satisfactory results. 
Although the aim of the Project was to promote self reli-
ance and independence, quality controls had to be carried 
out in Italy due to the cost of the necessary equipment. 
The external monitoring is important because it ensures a 
completely objective evaluation of the results.
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